Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/vepdegestrant-earns-fda-nod-esr1-mutated-breast-cancer-2026a1000e23?src=rss

Author :

Publish date : 2026-05-01 20:14:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

As RFK Jr. Downplays Rabies, CDC Staff Tells Docs It’s a Daily Threat

FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access

Related Posts

FDA Approves First Non-Antipsychotic Drug for Alzheimer’s Agitation

Novel Pulsed Field Ablation System Turns to High-Energy, Ultra-Short Zaps

Study Examines if Prenatal Exposure to Sedatives Is Linked to Psych Disorders

FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access

As RFK Jr. Downplays Rabies, CDC Staff Tells Docs It’s a Daily Threat

Which Former NIH Official Was Indicted?

FDA Approves First Non-Antipsychotic Drug for Alzheimer’s Agitation

Novel Pulsed Field Ablation System Turns to High-Energy, Ultra-Short Zaps

Study Examines if Prenatal Exposure to Sedatives Is Linked to Psych Disorders

FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

As RFK Jr. Downplays Rabies, CDC Staff Tells Docs It’s a Daily Threat

Which Former NIH Official Was Indicted?

FDA Opens Early Access to Novel Pancreatic Cancer Drug Generating Buzz

Categories

Archives